Skip to main content

How Prescription Drug Importation Can Lower Drug Prices

How Prescription Drug Importation Can Lower Drug Prices

The cost of prescription drugs in the U.S. is the highest in the developed world and is rising quickly. Americans often pay more for prescription drugs than individuals in comparable countries. According to a 2021 RAND Corporation study, U.S. prescription drug prices were 2.56 times higher, on average, than those in the 32 comparison countries. It’s no surprise many Americans struggle to afford the prescription drugs they need.

Addressing the lack of affordable prescription drugs is a top public health priority in the U.S. Prescription drug importation is one option some policymakers are pursuing to lower drug prices for Americans. While prescription drug importation has bipartisan public support, it remains a controversial issue with benefits and risks that must be examined.

This article explores the potential impacts of prescription drug importation on U.S. drug prices.

What is prescription drug importation?

Prescription drug importation is the practice of purchasing prescription drugs from another country and importing them to the U.S. The goal is to save money on prescription drug costs, as prices for many drugs are lower in other countries. Currently, it’s illegal to import prescription drugs into the U.S. from other countries except under limited circumstances. However, there have been proposals to legalize prescription drug importation to lower drug prices, increasing Americans’ access to affordable medications.

What is the current state of prescription drug importation?

Currently, U.S. law only permits certain drugs from Canada to be imported and sold in the U.S. under limited circumstances.

For an imported prescription drug to be sold in the U.S., it must meet the standards established in the Food and Drug Cosmetic Act of 1938 and be approved by the Food and Drug Administration. Only FDA-approved drugs manufactured in an FDA-inspected facility, intended for U.S. consumers and imported into the U.S. by drug manufacturers are permitted.

In rare circumstances, prescription drugs approved and manufactured in the U.S. and sent abroad may be imported back into the U.S. An example is when the importation is under the direction of the secretary of the U.S. Department of Health and Human Services for emergency medical purposes and by the original drug manufacturer in situations where a drug has been damaged or recalled.

Even though federal law allows prescription drug importation from Canada, the HHS secretary must still certify to Congress that importation will provide significant savings for U.S. consumers and will not threaten the general public’s health and safety.

In 2020, the Trump administration issued a final rule and final FDA guidance for prescription drug importation. This allowed states, territories and Native American tribes — and some wholesalers and pharmacists — to implement time-limited importation programs for certain drugs currently marketed in the U.S. from Canada. Under the administration’s final rule, states must submit their importation proposals to the HHS secretary for approval.

Similar to the Trump administration’s efforts, President Joe Biden issued an executive order in July 2021 directing the FDA to work with states to import prescription drugs from Canada. This proposal has strong bipartisan public support. Some states, including Florida, Vermont, Colorado and Maine, have enacted laws establishing prescription drug importation programs. However, to date, no plans have obtained the required certification by the HHS Secretary, largely due to safety concerns. The FDA is still working to implement a statutory pathway for the importation of drugs originally intended for foreign markets.

Recently, a U.S. district court dismissed a lawsuit by pharmaceutical industry members to stop state governments from importing prescription medications from Canada. This ruling may encourage more states to consider importing medications from Canada as a strategy to lower the costs of prescription drugs for Americans.

Can individuals import prescription drugs for personal use?

Except in limited circumstances, individuals cannot import FDA-approved drugs for personal use. Permission to import prescription drugs that have not been approved by the FDA is granted on a case-by-case basis and is usually only allowed to treat serious health conditions where there is no effective treatment available in the U.S.

However, some Americans purchase lower-cost prescription drugs from other countries, even though this is illegal in most situations. For example, according to a 2016 Kaiser Family Foundation poll, approximately 8% of respondents said they or someone in their household had imported a drug at some point. This equates to nearly 19 million Americans illegally importing medications. This willingness to import medications illegally is a strong indication that many Americans are unable to afford the costs of their prescription drugs.

Will prescription drug importation lower U.S. drug prices?

The goal of prescription drug importation is to lower drug prices for Americans. If successful, it could improve the health and well-being of the American public. However, despite its admirable goal, prescription drug importation remains controversial, with many doubting its merits.

The argument in favor of prescription drug importation is that it offers a way to provide safe, low-cost drugs to many Americans, which could improve access to needed and life-saving medications. Wholesale drug importation may also increase competitiveness among U.S. drug manufacturers, resulting in cost savings and lower prices. Canada’s single-payer health care system allows the government to negotiate directly with drug companies to reduce prices. So, allowing these lower-cost drugs to be marketed and sold in the U.S. may force U.S. drug companies to reduce their prices to remain competitive.

However, many are skeptical that prescription drug importation will lower drug costs in the U.S. Currently, many high-cost drugs, e.g., biologic products (insulin) and narcotics, cannot be imported. If importation of prescription drugs is legalized, potential costs savings could be limited if these exclusions continue.

Additionally, since any drugs imported to the U.S. would first go through Canadian negotiations with manufacturers, there’s no guarantee that prices would be lower. Before Canadian drugs could be sold in the U.S., they would likely need to be inspected, tested, repackaged, relabeled and tracked. This would likely require significant government oversight, potentially leading to increased costs.

Importing prescription drugs from Canada could also increase demand for those drugs in Canada, driving up prices. Every year, drug manufacturers typically allocate the number of drugs to be sold in each country individually. This is done by assessing past drug sales and estimating anticipated increases for the following year. Manufacturers are unlikely to increase Canada’s allotment of prescription drugs so those drugs can be redistributed to the U.S., especially since the U.S. is a larger and more lucrative market than Canada.

There are also concerns over whether importing drugs from Canada could meet U.S. demand. Further, it’s difficult to ensure the effectiveness, quality and safety of imported drugs.

Overall, lowering prescription drug costs is a priority for the American public. While there are questions about whether prescription drug importation will lower U.S. drug prices, it’s an option policymakers and states continue to explore.

Wrap-up: What employers can do

Reducing the cost of prescription drugs in the U.S. is critical. Prescription drug importation offers one way to potentially increase access and affordability to necessary and life-saving drugs for many Americans. This is a developing issue that employers should continue to monitor closely.

Contact HANYS Benefit Services today to learn more about employee benefits and how prescription drugs could influence your offerings. Our dedicated team of experts is ready to assist.


This Benefits Insights is not intended to be exhaustive nor should any discussion or opinions be construed as professional advice. © 2023 Zywave, Inc. All rights reserved.

Popular posts from this blog

Innovative employee retention strategies: 9 fresh ideas

Employee engagement and retention are pivotal in every sector, but they carry even more weight in the not-for-profit space, where resources are often limited. High turnover can be both costly and disruptive, impacting productivity and damaging morale. In an era of workforce evolution, to effectively retain their top talent, organizations must explore innovative employee retention strategies that go beyond conventional methods.  Engaged employees are distinguished by their higher productivity, motivation and loyalty, and they are more likely to stay with a company for the long term. Gallup recently updated its research article, The Benefits of Employee Engagement , finding that "low engagement teams typically endure turnover rates that are 18% to 43% higher than highly engaged teams."  In addition to turnover, disengaged employees negatively impact a company's financial health, with turnover costs averaging six to nine months of the departed employee's salary, accordin

Executive disability income protection program: C-suite FAQ

Implementing a comprehensive risk management strategy is imperative for C-level executives and senior management at HANYS member hospitals. One critical, but often overlooked component, is the executive disability income protection program. But what exactly is this program and why is it vital for high-income earners?   With increasing interest in executive disability income protection programs from C-suite executives, TruePlan Benefit and Retirement Advisors interviewed Bernard A. Gleeson, Director, Employee Benefit Services on Executive disability income protection programs FAQs.  What is an executive disability income protection program?  An executive disability income protection program (EDIPP) is a specialized form of disability insurance designed to supplement existing group disability plans offered by employers. These individual plans provide additional coverage beyond the typical monthly maximum benefit cap found in traditional employer-based offerings. By overlaying on top of g

Employer Q&A: What is Financial Wellness?

There is a significant gap between employees and employers regarding financial wellness programs, according to the Harvard Business Review . “80% of employees report being financially stressed. Only 28% of employers offer financial wellness programs,” the article states.   Similarly, Forbes highlights a 2023 Transamerican Institute study showing that 77% of workers consider financial wellness programs an important benefit.  With so much research on the need for these programs, what should employers do?  The first way employers can bridge this gap is to learn what financial wellness is and how it can improve an employee’s overall being. In this short Q&A, we introduce the topic and offer some essential tips to get started.  Q1: What is financial wellness?  A: Financial wellness refers to the sense of security a person feels about their financial situation in all aspects of their life. It means having control over day-to-day finances, being prepared for emergencies and having a plan